BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $43.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 53.52% from the company’s […]